Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma | Zendy

Franck Morschhauser | Zendy; Nathan Fowler | Zendy; Pierre Feugier | Zendy; Réda Bouabdallah | Zendy; Hervé Tilly | Zendy; M. Lia Palomba | Zendy; Christophe Fruchart | Zendy; Edward N. Libby | Zendy; Olivier Casasnovas | Zendy; Ian W. Flinn | Zendy; Corinne Haïoun | Zendy; Hervé Maisonneuve | Zendy; Loïc Ysebaert | Zendy; Nancy L. Bartlett | Zendy; Kamal Bouabdallah | Zendy; Pauline Brice | Zendy; Vincent Ribrag | Zendy; Nicolas Daguindau | Zendy; Steven Le Gouill | Zendy; Gian M. Pica | Zendy; Alejandro Martı́n | Zendy; Armando LópezGuillermo | Zendy; Jean-François Larouche | Zendy; Kiyoshi Ando | Zendy; María Gomes da Silva | Zendy; Marc André | Zendy; Pierre Zachée | Zendy; Laurie H. Sehn | Zendy; Kensei Tobinai | Zendy; Guillaume Cartron | Zendy; David Liu | Zendy; Jianming Wang | Zendy; Luc Xerri | Zendy; Gilles Salles | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Author(s) -

Franck Morschhauser,

Nathan Fowler,

Pierre Feugier,

Réda Bouabdallah,

Hervé Tilly,

M. Lia Palomba,

Christophe Fruchart,

Edward N. Libby,

Olivier Casasnovas,

Ian W. Flinn,

Corinne Haïoun,

Hervé Maisonneuve,

Loïc Ysebaert,

Nancy L. Bartlett,

Kamal Bouabdallah,

Pauline Brice,

Vincent Ribrag,

Nicolas Daguindau,

Steven Le Gouill,

Gian M. Pica,

Alejandro Martı́n,

Armando LópezGuillermo,

Jean-François Larouche,

Kiyoshi Ando,

María Gomes da Silva,

Marc André,

Pierre Zachée,

Laurie H. Sehn,

Kensei Tobinai,

Guillaume Cartron,

David Liu,

Jianming Wang,

Luc Xerri,

Gilles Salles

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1805104

Subject(s) - lenalidomide , rituximab , follicular lymphoma , medicine , oncology , lymphoma , follicular phase , multiple myeloma

Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research